Literature DB >> 21622284

Cancer stem cells: perspectives of new therapeutical approaches for breast cancer.

A Nicolini1, P Ferrari, M Fini, V Borsari, P Fallahi, A Antonelli, A Carpi, P Miccoli.   

Abstract

Currently stem cells are hypothesized to play a central role in the origin, spread and resistance to treatment of breast cancer. Common anticancer therapy is effective but transient, with tumor relapse and metastatic disease often occurring. For therapy to be more effective, debulking of differentiated tumors must occur followed by targeting of the remaining surviving often quiescent tumor stem cells. New therapeutics aimed at cancer stem cells are achieved through non immunological and immunological methods. The former include elective ABC drug transporters or the heat shock protein 90 inhibition, targeting the self-renewal signalling pathways or the EMT program, differentiation therapy, or other interventions to eliminate BrCSCs. The latter include targeting specific antigens expressed on BrCSCs, dendritic cells (DCs) based vaccination and blockers of the extrinsic signals at CSC niche. Here all these novel approaches related to breast cancer stem cells are described.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622284     DOI: 10.2741/239

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  5 in total

1.  Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy.

Authors:  Stuart K Calderwood
Journal:  Discov Med       Date:  2013-03       Impact factor: 2.970

2.  Increased expression of aldehyde dehydrogenase 1 A1 in nasopharyngeal carcinoma is associated with enhanced invasiveness.

Authors:  Weijian Hou; Weiling He; Yuhuang Li; Renqiang Ma; Zhangfeng Wang; Xiaolin Zhu; Qingling Fu; Yihui Wen; Huabin Li; Weiping Wen
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-27       Impact factor: 2.503

3.  Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.

Authors:  Zhi-Jie Hou; Xi Luo; Wei Zhang; Fei Peng; Bai Cui; Si-Jin Wu; Fei-Meng Zheng; Jie Xu; Ling-Zhi Xu; Zi-Jie Long; Xue-Ting Wang; Guo-Hui Li; Xian-Yao Wan; Yong-Liang Yang; Quentin Liu
Journal:  Oncotarget       Date:  2015-03-20

4.  Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.

Authors:  Aamir Ahmad; Ma'in Y Maitah; Kevin R Ginnebaugh; Yiwei Li; Bin Bao; Shirish M Gadgeel; Fazlul H Sarkar
Journal:  J Hematol Oncol       Date:  2013-10-07       Impact factor: 17.388

5.  Targeting the raft-associated Akt signaling in hepatocellular carcinoma.

Authors:  Yuan Liu; Ji-Yun Lv; Jian-Fei Shi; Mei Yang; Shu-Hong Liu; Zhi-Wei Li; Hong-Bo Wang; Shao-Geng Zhang; Zhen-Wen Liu; Jin-Biao Ding; Dong-Ping Xu; Jing-Min Zhao
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.